- AstraZeneca (NYSE:AZN) has closed on a deal to purchase the rights to lung drugs developed by Almirall (OTC:LBTSF), expanding the drug-maker's respiratory medicine portfolio.
- "Our agreement with Almirall brings strategic and long-term value to AstraZeneca's strong respiratory franchise, one of our key growth platforms," says CEO Pascal Soriot.
- The acquisition is worth up to $2.1B, with an initial $875M to be paid up front, and up to $1.2B in development.
From other sites
at CNBC.com (Jun 1, 2015)
Video at CNBC.com (Feb 11, 2015)
at CNBC.com (Feb 5, 2015)
at CNBC.com (Jan 14, 2015)
at CNBC.com (Jan 8, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs